Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 17 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 14 15 16 17 presentations: 1 to 25 of 425
Gene dysregulation in cancer: The view from chromosome neighborhoods
Richard A. Young
MIT Whitehead Inst. for Biomed. Research, Cambridge, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
Histone modifications and gene expression in cancer
Scott A. Armstrong
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
ATP-dependent chromatin remodeling complexes in human cancer
Cigall Kadoch
Dana-Farber Cancer Inst., Boston, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
Enhancer reprogramming during cancer progression
Christopher R. Vakoc
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
Lessons and opportunities for probe development in cancer research
David E. Uehling
Ontario Inst. for Cancer Research, Toronto, ON, Canada
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
Value proposition of chemical probes in the development of translational phenotypic bioassays towards target discovery and validation
Ivan Cornella-Taracido
Merck & Co., Boston, MA, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
Chemical probes of chromatin regulation: Case histories
Stephen V. Frye
Univ. of North Carolina at Chapel Hill, Chapel Hill, NC, United States
from AACR Annual Meeting 2017 on April 1, 2017 8:00 AM-10:00 AM
Invited Speaker
Jeffrey S. Miller
Univ. of Minnesota, Minneapolis, MN, United States
from AACR Annual Meeting 2017 on April 2, 2017 7:00 AM-8:00 AM
Cochair
Melissa M. Vasbinder
Ribon Therapeutics, Inc., Lexington, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-3:00 PM
The discovery and preclinical characterization of AMG 176: A first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma
Paul E. Hughes
Amgen, Inc., Thousand Oaks, CA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-3:00 PM
AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers
Alexander W Hird
AstraZeneca, Waltham, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-3:00 PM
ABBV-621: A best-in-class TRAIL-receptor agonist fusion protein that enhances optimal clustering for the treatment of solid and hematologic tumors
Susan E. Morgan-Lappe
AbbVie, North Chicago, IL, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-3:00 PM
Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer
Peter G. Smith
H3 Biomedicine Inc., Cambridge, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-3:00 PM
Durable efficacy and anticancer immunity following intratumoral administration of a combination of messenger RNAs encoding the costimulatory molecule OX40L and the cytokines IL-36g and IL-23
Josh P. Frederick
Onkaido, Cambridge, MA, United States
from AACR Annual Meeting 2017 on April 2, 2017 1:00 PM-3:00 PM
Introduction
Thomas Frank Gajewski
Univ. of Chicago, Chicago, IL, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
First-in-human PET imaging with the PD-L1 antibody 89Zr-atezolizumab
Frederike Bensch
University Medical Center Groningen, Groningen, Netherlands
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Discussant
David A. Mankoff
University of Pennsylvania, Philadelphia, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Intratumor and peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the first in-human trial
Roberta Zappasodi
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Discussant
Drew M. Pardoll
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Frederick L Locke
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19)
Frederick L. Locke
H. Lee Moffitt Cancer Center, Tampa, FL, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Discussant
Renier J. Brentjens
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141
Robert L. Ferris
University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141
Robert L. Ferris
University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
Discussant
Mario Sznol
Yale Cancer Ctr., New Haven, CT, United States
from AACR Annual Meeting 2017 on April 2, 2017 3:00 PM-5:15 PM
<< first | < prev page: of 17 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 14 15 16 17 presentations: 1 to 25 of 425